Cosmo Reports Excellent Final Full Year 2023 Financial Results - Increases Operating Profit Guidance for 2024 - Dividend of 2.00 per Share Will Be Proposed at EGM on 5 July 2024
Ad hoc announcement pursuant to Art. 53 LR Dublin, Ireland--(Newsfile Corp. - May 31, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) today announced its final audited results for the financial year 2023. Financial highlights As...
2024-05-31 6:09 PM EDT
Cosmo Pharmaceuticals' Shareholders Approve All Agenda Items at Annual General Meeting
Dublin, Ireland--(Newsfile Corp. - May 24, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) today announced that its shareholders approved all agenda items at today's annual general meeting of shareholders. A total of 7,417,916 ordinary shares in the share capital of Cosmo were represented at this annual general meeting of shareholders constituting 42.28% of the total outstanding...
2024-05-24 5:36 PM EDT
Cosmo Has Received Approval of an Extension in Respect of the Publication and the Filing of Its Annual Report 2023
Ad hoc announcement pursuant to Art. 53 LR Dublin, Ireland--(Newsfile Corp. - April 29, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) today announced that the company has been granted extension until 31 May 2024 to publish its 2023 annual report and to file such report with SIX Exchange Regulation AG. ...
2024-04-29 5:12 PM EDT
Cosmo Announces Leadership Changes
Ad hoc announcement pursuant to Art. 53 LR Giovanni Di Napoli appointed as new CEO effective from 24 May 2024. Current CEO Alessandro Della Chà to be appointed as new Chairman of the Board....
2024-04-25 1:32 AM EDT
Cosmo and Medtronic Unveil the Future of AI in GI: Genius Summit 2024 Reveals Innovations and Collaborations That Advance Endoscopic Care
Dublin, Ireland--(Newsfile Corp. - April 12, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) announces that Medtronic plc (NYSE: MDT), a global leader in healthcare technology, presented at the Genius Summit 2024 the latest advancements in artificial intelligence (AI) for endoscopic care by unveiling ColonPRO™, the latest generation software for the GI Genius™ intelligent endoscopy system developed by Cosmo IMD, along with...
2024-04-12 1:17 AM EDT
Cosmo Reports Excellent Preliminary Unaudited Full Year 2023 Core Financial Results - Record Guidance for 2024 - Doubles Dividend to 2.00 per Share
Ad hoc announcement pursuant to Art. 53 LR Medtronic deal accounted in 2024, to inject USD 200m cash. FDA approval of GI Genius new enhanced operating system. New GI drug development program announced. ...
2024-03-20 3:18 AM EDT
Cosmo Pharmaceuticals Announces Approval of Winlevi(R) in Australia
Dublin, Ireland--(Newsfile Corp. - March 19, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) reported today that its partner Sun Pharmaceutical Industries Limited (Reuters: SUN.BO) (Bloomberg: SUNP IN), (NSE: SUNPHARMA) (BSE: 524715) (“Sun Pharma”) has announced that the Australian Therapeutic Goods Administration (TGA) has granted regulatory approval for Winlevi® (clascoterone cream 1%). Winlevi® is indicated for the topical treatment of acne vulgaris in...
2024-03-19 2:40 AM EDT
Invitation to Cosmo's Investor Day and Full-Year 2023 Webcast - Zurich, 20 March 2024
Dublin, Ireland--(Newsfile Corp. - January 25, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) announced today that it will publish its Full-Year 2023 results on Wednesday, 20 March 2024 at 7:00 am CET. FY 2023 Results Webcast Cosmo invites investors, financial...
2024-01-25 1:30 AM EST
Cosmo Pharmaceuticals and Medtronic Forge Ahead in AI-Driven Care
Ad hoc announcement pursuant to Art. 53 LR Dublin, Ireland--(Newsfile Corp. - December 11, 2023) - Cosmo Pharmaceuticals (SIX: COPN) (XETRA: C43) (“Cosmo”) announces that its subsidiary Cosmo Intelligent Medical Devices has entered into a definitive agreement to expand its partnership with Medtronic plc (NYSE: MDT), a global leader in...
2023-12-11 2:02 AM EST